GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

NCT04535713 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Gemcitabine
DRUG: Doxorubicin
DRUG: Docetaxel
DRUG: Nivolumab

Sponsor

Sarcoma Oncology Research Center, LLC